Pharma Focus Asia

SignPath Pharma to Focus on Coronavirus Disease (COVID-19) by Developing Treatment for Acute Respiratory Distress Syndrome (ARDS)

Wednesday, March 18, 2020

SignPath Pharma today confirmed its commitment to developing a treatment for severe viral infections utilizing Lipocurc™, its patented intravenous formulation of liposomal curcumin.

SignPath’s Lipocurc™ is an intravenous treatment, proven to be safe in patients, that profoundly suppresses the multiple pro-inflammatory cytokines that cause severe lung damage (ARDS) in patients with COVID-19 infection caused by coronavirus 2 or SARS-CoV-2.

Patients with severe COVID-19 infection can develop fatal lung damage from a cytokine storm, a marked increase in pro-inflammatory cytokines such as Tumor Necrosis Factor-alpha, Interleukin-1 beta, Interleukin-6, Interleukin-8 and other cytokines.

Unlike other treatments now being studied to treat COVID-19 (which suppress only Interleukin-6), Lipocurc™ has the major advantage of not only safely suppressing interleukin-6 by 83%, it also profoundly suppresses two other extremely important proinflammatory cytokines associated with cytokine storm and fatal lung damage (TNF-alpha by 77% and IL-1 beta by 85%) as well as suppressing RANTES (CCL5), IL-8, MCP-1 and MIP-alpha.

Lipocurc’s proprietary formulation technology allows us to safely give liposomal curcumin intravenously in extremely high doses without cardiotoxicity, so we achieve blood levels 2,000 times greater than oral curcumin (which has extremely poor oral absorption.)

Unlike other potential treatments for cytokine storm, Lipocurc™ has been found to be without serious side effects in extensive animal studies and in human patients.

Even at very high doses, intravenous Lipocurc™ is well-tolerated and has shown no heart, lung, liver of kidney toxicity in two phase 1, escalating-dose, trials in 70 human patients.

SignPath is currently exploring opportunities to expedite the opportunities for utilizing Lipocurc™ in clinical settings for the treatment of patients afflicted with COVID-19 and other viral diseases which cause harm via the cytokine storm mechanism.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024